01711nas a2200241 4500008004100000022001400041245007300055210006900128260000800197300001200205490000700217520095500224653003901179653001101218653000901229653001701238653001401255100002601269700002301295700002501318700002501343856010101368 2019 eng d a1061-186X00acRGD functionalized nanocarriers for targeted delivery of bioactives0 acRGD functionalized nanocarriers for targeted delivery of bioact cFEB a111-1240 v273 a

The integrins αvβ3 play a very imperative role in angiogenesis and are overexpressed in endothelial cells of the tumor. Recent years have witnessed huge exploration in the field of αvβ3 integrin-mediated bioactive targeting for treatment of cancer. In these studies, the cRGD peptide has been employed extensively owing to their binding capacity to the αvβ3 integrin. Principally, RGD-based approaches comprise of antagonist molecules of the RGD sequence, drug-RGD conjugates, and most importantly tethering of the nanocarrier surface with the RGD peptide as targeting ligand. Targeting tumor vasculature or cells via cRGD conjugated nanocarriers have emerged as a promising technique for delivering chemotherapeutic drugs and imaging agents for cancer theranostics. In this review, primary emphasis has been given on the application of cRGD-anchored nanocarriers for targeted delivery of drugs, imaging agents, etc. for tumor therapy.

10aalpha(v)beta(3) integrin receptors10acancer10acRGD10ananocarriers10atargeting1 aGajbhiye, Kavita, Rai1 aGajbhiye, Virendra1 aSiddiqui, Imtiaz, A.1 aGajbhiye, Jayant, M. uhttps://library.ncl.res.in/content/crgd-functionalized-nanocarriers-targeted-delivery-bioactives02475nas a2200265 4500008004100000022001400041245013200055210006900187260000900256300001100265490000800276520158300284653002401867653000801891653001301899653001801912653001001930653002301940100002501963700002701988700002602015700001902041700002302060856012602083 2020 eng d a0378-517300aStimuli-responsive biodegradable polyurethane nano-constructs as a potential triggered drug delivery vehicle for cancer therapy0 aStimuliresponsive biodegradable polyurethane nanoconstructs as a cOCT  a1197810 v5883 a

Polyurethanes (PUs) constitute an essential class of stimuli-responsive and biodegradable material, which has significantly contributed to the advancement of polymers utilization in the biomedical field. The bio-erodible PUs construct an active corridor for facilitating drug into tumor cells, which has significantly impacted the progression of nano-micellar delivery systems. The self-assembled colloidal PUs pose distinctive features such as enhancing the solubility of hydrophobic chemotherapeutics, rapid cellular uptake, triggered erosion and drug release, bio-stimulus sensitivity, improvement in the targeting and proficiency of bioactive. Cationic PUs can easily be condensed with genetic material to form polyplexes and have shown excellent transfection efficiency for potential gene therapy against various cancers. Their modifiable chemistry offers a tool to impart the desired multifunctionality such as biocompatibility, sensitivity to pH, redox, temperature, enzyme, etc. and ligand conjugation for active targeting. These diverse exceptional properties make them excellent nano-carrier for a variety of bioactive, including chemotherapeutic drugs, DNA, RNA, and diagnostic moieties to the target tissue or cells. The PUs based nano-devices have certainly uncovered the path to achieve ideal systems for controlled personalized therapy. The literature discussed in this review shed light on the research innovations carried out in the last ten years for the development of multifunctional PUs for triggered delivery of bioactive to treat various cancers.

10aCancer nanomedicine10aGSH10amicelles10aPolyurathanes10aredox10aStimuli-responsive1 aGajbhiye, Kavita, R.1 aChaudhari, Bhushan, P.1 aPokharkar, Varsha, B.1 aPawar, Atmaram1 aGajbhiye, Virendra uhttps://library.ncl.res.in/content/stimuli-responsive-biodegradable-polyurethane-nano-constructs-potential-triggered-drug02874nas a2200313 4500008004100000022001400041245012400055210006900179260000900248300001100257490000900268520183000277653002402107653001402131653001802145653002702163653001502190653001602205100002102221700002202242700002302264700002002287700002202307700002502329700002602354700002302380700002502403856013202428 2022 eng d a0022-286000aNovel 3-fluoro-4-morpholinoaniline derivatives: synthesis and assessment of anti-cancer activity in breast cancer cells0 aNovel 3fluoro4morpholinoaniline derivatives synthesis and assess cAPR  a1321270 v12533 aHeterocyclic morpholine compounds are well-known for their anti-cancer activity. In this study, novel morpholine and its sulfonamide derivatives were designed and synthesized as potential anti-tumor agents. The new compounds were obtained from amine derivatives via nucleophilic addition reactions, providing the desired products in 70 to 90% yield. The docking analysis was performed for all thirty-one compounds. Out of them, we represent the docking poses for compounds NAM-5 and NAM-7 as representatives. After docking analysis, compounds NAM-5 and NAM- 7 were tested for in vitro antitumor activity against breast cancer cell lines (MCF-7 and MDA-MB-231) and healthy mouse embryonic fibroblast cell line (3T3L-1). Amongst these, sulfonamide group-containing compound NAM-5 showed significant anti-proliferative activity with IC50 of 1.811 mu M and 2.143 mu M for MCF-7 and MDA-MB-231 cells, respectively. On the other hand, NAM-7 showed good anti-proliferative activity against MCF-7 (IC50 1.883 mu M) but slightly lower activity against MDA-MB-231 cells (IC50 4.688 mu M). The activity of both the compound was also tested on 3T3L-1 Cell line which showed activity similar to clinically approved anti-cancer drug doxorubicin (DOX). The cell death analysis by flow-cytometry confirmed apoptosis mediated cell death in 3T3L-1, MCF-7 and MDA-MB-231 cells when treated with the NAM-5 and NAM-7, respectively. The results demonstrated that the synthesized sulfonamide derivatives have significant potential as anti-cancer agents and have a substantial importance in cancer therapeutics with favourable safety profile. Structural analysis of docked poses of sulfonamide derivatives attempts to shed light on the structural basis of sulfonamide derivatives based anti-cancer effect. (C) 2021 Elsevier B.V. All rights reserved.10aAnticancer activity10aApoptosis10aBreast cancer10aHeterocyclic compounds10aMorpholine10aSulfonamide1 aMore, Namita, A.1 aJadhao, Nitin, L.1 aMeshram, Rohan, J.1 aTambe, Prajakta1 aSalve, Rajesh, A.1 aSabane, Jagjivan, K.1 aSawant, Sanskruti, N.1 aGajbhiye, Virendra1 aGajbhiye, Jayant, M. uhttps://library.ncl.res.in/content/novel-3-fluoro-4-morpholinoaniline-derivatives-synthesis-and-assessment-anti-cancer-activity03002nas a2200265 4500008004100000022001400041245014400055210006900199260000800268300001400276490000800290520209300298653001502391653000802406653003602414653001202450653001902462653001502481653002302496100001802519700001802537700002702555700002302582856013102605 2023 eng d a0022-354900aAptamer tethered bio-responsive mesoporous silica nanoparticles for efficient targeted delivery of paclitaxel to treat ovarian cancer cells0 aAptamer tethered bioresponsive mesoporous silica nanoparticles f cMAY a1450-14590 v1123 a

Ovarian cancer is the leading cause of cancer deaths in female patients. The current therapeutics in ovarian cancer are limited and inefficient in curing the disease. To tackle this, we have synthesized tetrasulfide deriv-ative of silica doped, biodegradable, glutathione-responsive targeted mesoporous silica nanoparticles modi-fied with heterobifunctional polyethylene glycol as a linker and mucin-1 aptamer for triggered paclitaxel delivery to the ovarian cancer cells. Degradable mesoporous silica nanoparticles were synthesized by a modi-fied sol-gel method with tetraethyl orthosilicate and Bis (triethoxysilylpropyl) tetrasulfide. The degradable mesoporous silica nanoparticles were characterized by dynamic light scattering, Fourier-transform infrared spectroscopy, Scanning electron microscopy and Transmission electron microscopy. The degradable mesopo-rous silica nanoparticles had good paclitaxel encapsulation efficiency and glutathione-responsive paclitaxel release ability. The glutathione utilization assay and visual destruction observed within 10 days in transmis-sion electron microscopy images confirmed the degradation of the mesoporous silica nanoparticles in the tumor cell environment. The targeted degradable mesoporous silica nanoparticles were efficiently taken up by ovarian cancer cell lines OVACAR-3 and PA-1. The cytotoxicity of bare mesoporous silica nanoparticles evaluated on NIH-3T3 cell line showed good biocompatibility (>90% cell viability). Significant toxicity on OVACAR-3 (IC50 25.66 nM) and PA-1 (IC50 42.93 nM) cell lines was observed when treated with paclitaxel-loaded targeted degradable mesoporous silica nanoparticles. Results of this study demonstrated that mucin-1 targeted, glutathione-responsive mesoporous silica nanoparticles loaded with paclitaxel had a significant antitumor effect on ovarian cancer cells. All these findings demonstrated that developed nano-formulation could be suitable for ovarian cancer treatment. & COPY; 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.

10aDegradable10aGSH10aMesoporous silica nanoparticles10aMucin-110aOvarian cancer10aPaclitaxel10aStimuli-responsive1 aSalve, Rajesh1 aKumar, Pramod1 aChaudhari, Bhushan, P.1 aGajbhiye, Virendra uhttps://library.ncl.res.in/content/aptamer-tethered-bio-responsive-mesoporous-silica-nanoparticles-efficient-targeted-delivery02536nas a2200229 4500008004100000022001400041245013200055210006900187260000800256300001100264490000800275520170400283653001801987653002802005653002902033653002702062100002102089700001802110700002302128700002702151856012802178 2023 eng d a0009-308400aChallenges and emerging strategies for next generation liposomal based drug delivery: an account of the breast cancer conundrum0 aChallenges and emerging strategies for next generation liposomal cJAN a1052580 v2503 a

The global cancer burden is witnessing an upsurge with breast cancer surpassing other cancers worldwide. Furthermore, an escalation in the breast cancer caseload is also expected in the coming years. The conventional therapeutic regimens practiced routinely are associated with many drawbacks to which nanotechnological in-terventions offer a great advantage. But how eminent could liposomes and their advantages be in superseding these existing therapeutic modalities? A solution is reflected in this review that draws attention to a decade-long journey embarked upon by researchers in this wake. This text is a comprehensive discussion of liposomes, the front runners of the drug delivery systems, and their active and passive targeting approaches for breast cancer management. Active targeting has been studied over the decade by many receptors overexpressed on the breast cancer cells and passive targeting with many drug combinations. The results converge on the fact that the actively targeted formulations exhibit a superior efficacy over their non-targeted counterparts and the all lipo-somal formulations are efficacious over the free drugs. This undoubtedly underlines the dominion of liposomal formulations over conventional chemotherapy. These investigations have led to the development of different liposomal formulations with active and passive targeting capacities that could be explored in depth. Acknowl-edging and getting a deeper insight into the liposomal evolution through time also unveiled many imperfections and unchartered territories that can be explored to deliver dexterous liposomal formulations against breast cancer and more in the clinical trial pipeline.

10aBreast cancer10aLiposomal metamorphosis10aReceptor-ligand dynamics10aTargeted Drug Delivery1 aMoudgil, Aliesha1 aSalve, Rajesh1 aGajbhiye, Virendra1 aChaudhari, Bhushan, P. uhttps://library.ncl.res.in/content/challenges-and-emerging-strategies-next-generation-liposomal-based-drug-delivery-account02198nas a2200253 4500008004100000022001400041245010700055210006900162260000800231300001100239490000800250520133700258653001801595653001801613653001901631653002301650100001901673700002301692700002001715700002301735700002301758700003201781856013101813 2025 eng d a1552-497300aGold nanorods (GNRs): a golden nano compass to navigate breast cancer by multimodal imaging approaches0 aGold nanorods GNRs a golden nano compass to navigate breast canc cFEB ae355430 v1133 a

The ongoing rise in the incidences of breast cancer cases has concerned medical and scientific personnel around the world. Adequate treatment of cancer predominantly relies on the pertinent diagnosis of the type of cancer as well as other molecular and cellular details at the initial stage only. Surprisingly, up till now, there is no single, self-reliant imaging modality that helps to systematically find out the anatomical and functional events taking place inside the body. This resulted in the advent of the multimodal imaging concept, which encompasses the integration of complementary imaging modalities by designing multimodal imaging probes. Gold nanorods (GNRs) are extremely popular and effective nanoparticles for multimodal bioimaging due to their unique properties. Researchers have designed varieties of stable and biocompatible GNR-based probes for targeted and nontargeted multimodal imaging of breast cancer. However, there is a lack of investigations on the in vivo fate and the toxicity of GNRs. Thus, their preclinical to clinical translation can be attained by comprehensively determining the in vivo fate and toxicity of GNRs. The review provides details about the GNRs-based nanoprobes fabricated so far for breast cancer imaging, which, by consequent studies, can be taken up to clinical usage.

10aBreast cancer10aGold nanorods10aimaging probes10aMultimodal Imaging1 aVarma, Sanjana1 aBamb, Aagam, Lalit1 aHaldar, Niladri1 aGajbhiye, Virendra1 aAmalnerkar, Dinesh1 aChaudhari, Bhushan, Pradosh uhttps://library.ncl.res.in/content/gold-nanorods-gnrs-golden-nano-compass-navigate-breast-cancer-multimodal-imaging-approaches